MK-7762   Click here for help

GtoPdb Ligand ID: 13542

Synonyms: MK7762 | TBD09
Compound class: Synthetic organic
Comment: MK-7762 (also known as TBD09) is the oxazolidinone antibacterial compound claimed in Merck's patent WO2021188606A1 [1]. It is being developed as a treatment for tuberculosis (TB) by Merck and the Bill & Melinda Gates Medical Research Institute.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 9
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 113.63
Molecular weight 419.4
XLogP 0.63
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES COC(=O)NC[C@H]1CN(C2=CC(=C(C(=C2)F)N3CCS(=O)(=O)CC3)F)C(=O)O1
Isomeric SMILES O=C1N(C[C@H](CNC(OC)=O)O1)C2=CC(F)=C(C(F)=C2)N3CCS(=O)(=O)CC3
InChI InChI=1S/C16H19F2N3O6S/c1-26-15(22)19-8-11-9-21(16(23)27-11)10-6-12(17)14(13(18)7-10)20-2-4-28(24,25)5-3-20/h6-7,11H,2-5,8-9H2,1H3,(H,19,22)/t11-/m0/s1
InChI Key CCYKSCLMFZLAJH-NSHDSACASA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
A first-in-human Phase 1 clinical trial, to assess the safety, tolerability, and pharmacokinetics of MK-7762 in healthy volunteers (NCT05824091), has been completed.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
The antibacterial MMOA of oxazolidinones is inhibition of protein synthesis by blocking function of the bacterial 50S ribosomal subunit [2].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05824091 Safety, Tolerability, Pharmacokinetics (PK), and Food Effect of MK-7762 in Healthy Adults Phase 1 Interventional Bill & Melinda Gates Medical Research Institute